Berman Howard 4

What Happened Berman Howard, Executive Chairman and a director of Coya Therapeutics (COYA), was granted a derivative award on 2026-01-22 covering 15,257 shares. The filing reports an acquisition price of $0.00 (derivative); the grant is recorded as an award (transaction code A). The Form 4 was filed on 2026-01-26 (timely).

Key Details

• Transaction date: 2026-01-22; Filing date: 2026-01-26 (timely filing).
• Security: derivative award covering 15,257 shares; price reported as $0.00; total reported value $0 (derivative).
• Vesting: per footnote, the shares underlying the option vest in monthly installments over the next 36 months, subject to continuous service.
• Change in control: upon a change in control, the shares underlying the option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan (as amended).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context This filing documents a grant of a derivative award (an option-like award that vests over time). Such awards give the insider the right to acquire shares in the future if vesting conditions are met; they are not an immediate open-market purchase or sale. The filing contains no indication of immediate sale (cashless exercise) or a 10b5-1 plan.